- Acumen Powered by Robins Kaplan LLP®
- Affirmative Recovery
- American Indian Law and Policy
- Antitrust and Trade Regulation
- Appellate Advocacy and Guidance
- Business Litigation
- Civil Rights and Police Misconduct
- Class Action Litigation
- Commercial/Project Finance and Real Estate
- Corporate Governance and Special Situations
- Corporate Restructuring and Bankruptcy
- Domestic and International Arbitration
- Entertainment and Media Litigation
- Health Care Litigation
- Insurance and Catastrophic Loss
- Intellectual Property and Technology Litigation
- Mass Tort Attorneys
- Medical Malpractice Attorneys
- Personal Injury Attorneys
- Telecommunications Litigation and Arbitration
- Wealth Planning, Administration, and Fiduciary Disputes
Acumen Powered by Robins Kaplan LLP®
Ediscovery, Applied Science and Economics, and Litigation Support Solutions
-
December 5, 2024Jake Holdreith Named to Twin Cities Business Top 100
-
December 4, 2024Robins Kaplan Obtains $10.5 Million Post-Verdict in Landmark Aerosol Dust Remover Abuse Case
-
December 2, 2024Robins Kaplan LLP Announces 2025 Partners
-
December 11, 20242024 Year in Review: eDiscovery and Artificial Intelligence
-
December 12, 2024Strategies for Licensing AI: A Litigation Perspective
-
December 2024A Landmark Victory for Disabled Homeless Veterans: Q&A with the Trial Team
-
November 8, 2024Trademark tensions on the track: Court upholds First Amendment protections in Haas v. Steiner
-
November 8, 2024Destination Skiing And The DOJ's Mountain Merger Challenge
-
September 16, 2022Uber Company Systems Compromised by Widespread Cyber Hack
-
September 15, 2022US Averts Rail Workers Strike With Last-Minute Tentative Deal
-
September 14, 2022Hotter-Than-Expected August Inflation Prompts Massive Wall Street Selloff
Find additional firm contact information for press inquiries.
Find resources to help navigate legal and business complexities.
Read our attorneys' take on the latest news and trends in the legal and business industries.
GENERICally Speaking Hatch Waxman Bulletin
The Hatch-Waxman Litigation practice group at Robins Kaplan LLP is pleased to offer the latest edition of their quarterly publication regarding ANDA patent litigation issues and the generics business.
GENERICally Speaking Q3
Third Quarter
The third quarter issue of the GENERICally Speaking campaign provides you and your company with some of the knowledge beneficial to remaining attentive to the complexity of ANDA patent litigation.
In this issue:
- United Therapeutics Corp. v. Liquidia Technologies, Inc.
Tyvaso® (treprostinil)
The district court did not clearly err in its factual findings based on the record evidence that the claims of one of the patents-in-suit were not invalid and infringed, and that the claims of the other patent-in-suit were invalid. - CMP Development, LLC v. Amneal Pharms. LLC
CaroSpir® (spironolactone)
Because tragacanth powder did not act as a suspending agent in the same way as xanthan gum, plaintiff did not meet its burden of establishing infringement under the doctrine of equivalents. - Novartis Pharms. Corp. v. Alembic Pharms. Ltd.
Entresto® (sacubitril/valsartan)
The court reiterated a more relaxed pleading standard in ANDA litigations by not requiring plaintiff to rely on ANDAs, product samples, and other confidential information from a first litigation as factual predicate in the complaint of a follow-on patent litigation. - Takeda Pharms. U.S.A., Inc. v. Mylan Pharms., Inc.
Colcrys® (colchicine)
Court grants summary judgment allowing ANDA holder to launch early given unambiguous terms of settlement agreement resolving previous litigation. - Allergan USA, Inc. v. MSN Labs. Private Ltd.
Viberzi® (eluxadoline)
The asserted claims were invalid for lack of adequate written description where (i) there was no description of a pharmaceutical formulation that did not require a glidant and (ii) the claims claimed “fillers” and “disintegrants,” but only one species of each was described throughout the specification. - Zogenix, Inc. v. Apotex Inc.
Fintepla® (fenfluramine HCl)
Magistrate Judge’s report was adopted and Defendant’s motion to dismiss was granted based on admissions in Plaintiff’s labeling concerning the administration of the accused product. - Purdue Pharma L.P. v. Accord Healthcare Inc.,
OxyContin® (oxycodone HCl)
Motion for judgment on the pleadings on the basis of collateral estoppel was denied because triable issues of fact exist that were undecided in the prior trial opinion. - UCB, Inc. v. Annora Pharma Priv. Ltd.
Briviact® (brivaracetam)
Asserted claim was not obvious when defendants could not show a reasonable expectation of success in modifying a compound to increase lipophilicity to increase antiepileptic activity. - Taiho Pharm. Co., Ltd. v. Eugia Pharma Specialties Ltd.
Lonsurf® (trifluorothymidine / tipiracil)
The asserted claim was not invalid because (i) a skilled artisan would not have been motivated to administer the claimed drug in twice-daily doses; and (ii) the patent specification adequately described clinical trials where cancer patients received the combination therapy by oral administration twice-daily. - Orexo AB v. Sun Pharm. Indus. Ltd.
Zubsolv® (buprenorphine/naloxone)
Trial court found that the ANDA product would infringe the asserted claims, and that those claims were not indefinite, non-enabled, inadequately described, or obvious. - In re Entresto (Sacubitril/Valsartan) Patent Litigation
Entresto® (sacubitril/valsartan)
Because the patented complexes were unknown as of the priority date of the patent-in-suit, the inventors did not possess the invention and therefore could not have adequately described them. - Novartis Pharms. Corp. v. Mylan Pharms. Inc.
Entresto® (sacubitril / valsartan)
Testing confirmed that Defendant’s API met the purity specification limitations in the asserted claims, and therefore infringed the patents-in-suit.
Relevant ANDA Updates highlighted in this issue:
Related Professionals
New Drug Applications and 505(b)(2) Applications
Reported settlements in federal district court cases
Abbreviated New Drug Applications and 505(b)(2) Applications
Federal district court cases that are filed pursuant to the Hatch-Waxman Act
CaroSpir® (spironolactone)
Entresto® (sacubitril/valsartan)
Viberzi® (eluxadoline)
Colcrys® (colchicine)
OxyContin® (oxycodone HCl)
Fintepla® (fenfluramine HCl)
Briviact® (brivaracetam)
Lonsurf® (trifluorothymidine / tipiracil)
Tyvaso® (treprostinil)
Zubsolv® (buprenorphine/naloxone)
Entresto® (sacubitril/valsartan)
Entresto® (sacubitril / valsartan)
Any information that you send us in an e-mail message should not be confidential or otherwise privileged information. Sending us an e-mail message will not make you a client of Robins Kaplan LLP. We do not accept representation until we have had an opportunity to evaluate your matter, including but not limited to an ethical evaluation of whether we are in a conflict position to represent you. Accordingly, the information you provide to us in an e-mail should not be information for which you would have an expectation of confidentiality.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.
If you are interested in having us represent you, you should call us so we can determine whether the matter is one for which we are willing or able to accept professional responsibility. We will not make this determination by e-mail communication. The telephone numbers and addresses for our offices are listed on this page. We reserve the right to decline any representation. We may be required to decline representation if it would create a conflict of interest with our other clients.
By accepting these terms, you are confirming that you have read and understood this important notice.